You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer
|
|---|---|
| Published in |
Molecular Oncology, January 2016
|
| DOI | 10.1016/j.molonc.2016.01.006 |
| Pubmed ID | |
| Authors |
Francesca Riva, Oleksii I. Dronov, Dmytro I. Khomenko, Florence Huguet, Christophe Louvet, Pascale Mariani, Marc-Henri Stern, Olivier Lantz, Charlotte Proudhon, Jean-Yves Pierga, Francois-Clement Bidard |
| Abstract |
Pancreatic ductal adenocarcinoma (PDAC) is the most frequent pancreatic cancer type and is characterized by a dismal prognosis due to late diagnosis, local tumor invasion, frequent distant metastases and poor sensitivity to current therapy. In this context, circulating tumor cells and circulating tumor DNA constitute easily accessible blood-borne tumor biomarkers that may prove their clinical interest for screening, early diagnosis and metastatic risk assessment of PDAC. Moreover these markers represent a tool to assess PDAC mutational landscape. In this review, together with key biological findings, we summarize the clinical results obtained using "liquid biopsies" at the different stages of the disease, for early and metastatic diagnosis as well as monitoring during therapy. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Turkey | 1 | 25% |
| China | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 3 | 75% |
| Members of the public | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 194 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 192 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 34 | 18% |
| Student > Ph. D. Student | 29 | 15% |
| Student > Master | 21 | 11% |
| Student > Bachelor | 17 | 9% |
| Other | 17 | 9% |
| Other | 30 | 15% |
| Unknown | 46 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 56 | 29% |
| Biochemistry, Genetics and Molecular Biology | 43 | 22% |
| Agricultural and Biological Sciences | 17 | 9% |
| Engineering | 5 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 2% |
| Other | 13 | 7% |
| Unknown | 56 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2016.
All research outputs
#16,011,208
of 25,775,807 outputs
Outputs from Molecular Oncology
#1,066
of 1,764 outputs
Outputs of similar age
#216,991
of 406,151 outputs
Outputs of similar age from Molecular Oncology
#17
of 30 outputs
Altmetric has tracked 25,775,807 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,764 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,151 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.